Truist Securities Maintains Buy on BridgeBio Pharma, Raises Price Target to $86

Benzinga · 3d ago
Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises the price target from $80 to $86.